National Bank of Canada FI Has $12.34 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

National Bank of Canada FI lifted its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 53.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 158,329 shares of the company's stock after purchasing an additional 55,473 shares during the period. National Bank of Canada FI's holdings in AstraZeneca were worth $12,335,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Stratos Wealth Advisors LLC grew its holdings in shares of AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company's stock worth $522,000 after buying an additional 133 shares in the last quarter. Carnegie Investment Counsel grew its stake in AstraZeneca by 0.8% during the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company's stock valued at $1,347,000 after acquiring an additional 138 shares in the last quarter. Crumly & Associates Inc. raised its holdings in AstraZeneca by 2.2% in the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company's stock valued at $518,000 after acquiring an additional 143 shares during the last quarter. Sunpointe LLC lifted its stake in AstraZeneca by 4.5% in the 2nd quarter. Sunpointe LLC now owns 3,419 shares of the company's stock worth $267,000 after purchasing an additional 147 shares in the last quarter. Finally, Argonautica Private Wealth Management Inc. boosted its holdings in shares of AstraZeneca by 4.0% during the 2nd quarter. Argonautica Private Wealth Management Inc. now owns 3,874 shares of the company's stock worth $302,000 after purchasing an additional 149 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Price Performance

Shares of NASDAQ:AZN traded up $0.22 during trading on Wednesday, reaching $67.40. The stock had a trading volume of 7,351,347 shares, compared to its average volume of 5,315,825. The business's 50-day moving average price is $70.86 and its 200 day moving average price is $76.93. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The stock has a market capitalization of $208.98 billion, a PE ratio of 32.14, a P/E/G ratio of 1.22 and a beta of 0.45. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company's revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter last year, the business posted $0.87 EPS. As a group, equities analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a "sell" rating to a "neutral" rating in a research note on Wednesday, November 20th. Finally, Erste Group Bank raised shares of AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, AstraZeneca presently has a consensus rating of "Moderate Buy" and a consensus price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.